Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1-based Therapy Discontinuation
NCT07729332Phase 4Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2026
- Primary completion
- Jul 2031
- Countries
- 1
01
Overview
A Phase 4 trial of orforglipron in obesity, sponsored by Massachusetts General Hospital. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
orforglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07729332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729332.